Triple-Negative Breast Carcinoma

molecular subtype

Identifier: CI-CAN-00008567
Entity page: /cancer/triple-negative-breast-carcinoma ↗
Edges: 1,187

Neighbours: 3 genes6 variants21 drugs10 trials
Drawn: 40 of 40 neighbours (cap 60); table lists every fetched edge

Accepted: cancer:<slug>, gene:<symbol>, variant:<slug>, drug:<slug>, trial:<NCT id>, or a bare CI id. Find slugs with search.

Most connectedLung Non-Small Cell Carcinoma 3,149 Malignant Colorectal Neoplasm 1,866 ABL1 298 EGFR 276 Imatinib 450 Dasatinib 321

Neighbourhood

Radial view

Focus at the centre; neighbours grouped by entity type. Click a node to re-centre the graph on it; ↗ opens the entity page. Hover a spoke for relationship, evidence level, cancer context and source.

Edges

Every edge, grouped by relationship

Source-native edges first (aggregated per neighbour, direction, evidence level and source), then derived registry links. Up to 15 per relationship (10 trials); “show all” raises one group to 200.

Relationship	Neighbour	Direction	Evidence level	Cancer context	Support	Claim	Source	Expand
Triple-Negative Breast Carcinoma approved for …APPROVED_FOR5 of 5
← approved for	Pembrolizumabmonoclonal_antibody	supports	FDA ORIG	Triple-Negative Breast Carcinoma	1	Regulatory	openfda	graph →
← approved for	Datopotamab Deruxtecanadc	supports	FDA ORIG

Paths

Strongest chains

Gene → variant → drug chains anchored in this cancer (or a descendant), ranked by source-native evidence level then support, with the approval and trial registry hops when they exist.

BRCA1 Loss-of-function Olaparib11 active / 21 trials
Curatedlevel Asensitivity· support 1civicObservedcohort frequency not yet available for BRCA1 in this cancerno approval record in this cancercontext: Triple-Negative Breast Carcinoma
BRCA2 Loss-of-function Olaparib11 active / 21 trials
Curatedlevel Asensitivity· support 1civicObservedcohort frequency not yet available for BRCA2 in this cancerno approval record in this cancercontext: Triple-Negative Breast Carcinoma
BRCA1 Mutation Carboplatin52 active / 102 trials
Curatedlevel Bsensitivity· support 1civicObservedcohort frequency not yet available for BRCA1 in this cancerno approval record in this cancercontext: Triple-Negative Breast Carcinoma
BRCA1 Mutation Cisplatin7 active / 21 trials
Curatedlevel Bsensitivity· support 1civicObservedcohort frequency not yet available for BRCA1 in this cancerno approval record in this cancercontext: Triple-Negative Breast Carcinoma
BRCA2 Mutation Carboplatin52 active / 102 trials
Curatedlevel Bsensitivity· support 1civicObservedcohort frequency not yet available for BRCA2 in this cancerno approval record in this cancercontext: Triple-Negative Breast Carcinoma
BRCA2 Mutation Cisplatin7 active / 21 trials
Curatedlevel Bsensitivity· support 1civicObservedcohort frequency not yet available for BRCA2 in this cancerno approval record in this cancercontext: Triple-Negative Breast Carcinoma
AKT3 Overexpression Pan-AKT Kinase Inhibitor GSK6906930 active / 0 trials
Curatedlevel Esensitivity· support 1civicObservedcohort frequency not yet available for AKT3 in this cancerno approval record in this cancercontext: Triple-Negative Breast Carcinoma

Each hop keeps its own claim category: cohort alteration frequency (observed, cases ≥ 20), CIViC predictive edge (curated, level as stated by CIViC), regulatory approval (authority, jurisdiction, date as published), trial count (registry). A missing hop is shown as missing — never filled in. Not treatment guidance.

Triple-Negative Breast Carcinoma predicts response to …PREDICTS_RESPONSE_TO9 of 9
in context · predicts response to	BRCA2 Loss-of-function → predicts response to Olaparib	sensitivity	A	Triple-Negative Breast Carcinoma	1	Curated	civic	graph →
in context · predicts response to	BRCA1 Loss-of-functionloss_of_heterozygosity → predicts response to Olaparib	sensitivity	A	Triple-Negative Breast Carcinoma	1	Curated	civic	graph →
in context · predicts response to	BRCA1 Mutationother → predicts response to Olaparib	resistance	B	Triple-Negative Breast Carcinoma	1	Curated	civic	graph →
in context · predicts response to	BRCA2 Mutationother → predicts response to Carboplatin	sensitivity	B	Triple-Negative Breast Carcinoma	1	Curated	civic	graph →
in context · predicts response to	BRCA2 Mutationother → predicts response to Cisplatin	sensitivity	B	Triple-Negative Breast Carcinoma	1	Curated	civic	graph →
in context · predicts response to	BRCA1 Mutationother → predicts response to Carboplatin	sensitivity	B	Triple-Negative Breast Carcinoma	1	Curated	civic	graph →
in context · predicts response to	BRCA1 Mutationother → predicts response to Cisplatin	sensitivity	B	Triple-Negative Breast Carcinoma	1	Curated	civic	graph →
in context · predicts response to	High → predicts response to Immune Checkpoint Inhibitor	sensitivity	E	Triple-Negative Breast Carcinoma	1	Curated	civic	graph →
in context · predicts response to	AKT3 Overexpressionexpression → predicts response to Pan-AKT Kinase Inhibitor GSK690693	sensitivity	E	Triple-Negative Breast Carcinoma	1	Curated	civic	graph →

Triple-Negative Breast Carcinoma associated with …ASSOCIATED_WITH5 of 5
← associated with	BRCA2	supports	A	Triple-Negative Breast Carcinoma	1	Curated	civic	graph →
← associated with	BRCA1	supports	A	Triple-Negative Breast Carcinoma	1	Curated	civic	graph →
← associated with	BRCA1 2 source records aggregated	supports	B	Triple-Negative Breast Carcinoma	2	Curated	civic	graph →
← associated with	BRCA2	supports	B	Triple-Negative Breast Carcinoma	1	Curated	civic	graph →
← associated with	AKT3	supports	E	Triple-Negative Breast Carcinoma	1	Curated	civic	graph →

Triple-Negative Breast Carcinoma investigated for …INVESTIGATED_FOR15 of 77show all (up to 200)
← investigated for	Olaparibsmall_molecule 2 source records aggregated	supports	A	Triple-Negative Breast Carcinoma	2	Curated	civic	graph →
← investigated for	Carboplatinsmall_molecule 2 source records aggregated	supports	B	Triple-Negative Breast Carcinoma	2	Curated	civic	graph →
← investigated for	Cisplatinsmall_molecule 2 source records aggregated	supports	B	Triple-Negative Breast Carcinoma	2	Curated	civic	graph →
← investigated for	Olaparibsmall_molecule	supports	B	Triple-Negative Breast Carcinoma	1	Curated	civic	graph →
← investigated for	Sacituzumab Govitecanadc	unknown	4	Triple-Negative Breast Carcinoma	1	Curated	chembl	graph →
← investigated for	Atezolizumabmonoclonal_antibody	unknown	4	Triple-Negative Breast Carcinoma	1	Curated	chembl	graph →
← investigated for	Vinorelbinesmall_molecule	unknown	3	Triple-Negative Breast Carcinoma	1	Curated	chembl	graph →
← investigated for	Toripalimabmonoclonal_antibody	unknown	3	Triple-Negative Breast Carcinoma	1	Curated	chembl	graph →
← investigated for	Pembrolizumabmonoclonal_antibody	unknown	3	Triple-Negative Breast Carcinoma	1	Curated	chembl	graph →
← investigated for	Pegfilgrastimother	unknown	3	Triple-Negative Breast Carcinoma	1	Curated	chembl	graph →
← investigated for	Paclitaxelsmall_molecule	unknown	3	Triple-Negative Breast Carcinoma	1	Curated	chembl	graph →
← investigated for	Ipatasertibsmall_molecule	unknown	3	Triple-Negative Breast Carcinoma	1	Curated	chembl	graph →
← investigated for	Gemcitabinesmall_molecule	unknown	3	Triple-Negative Breast Carcinoma	1	Curated	chembl	graph →
← investigated for	Filgrastimother	unknown	3	Triple-Negative Breast Carcinoma	1	Curated	chembl	graph →
← investigated for	Eribulinsmall_molecule	unknown	3	Triple-Negative Breast Carcinoma	1	Curated	chembl	graph →

Triple-Negative Breast Carcinoma investigated in trials for …INVESTIGATED_IN_TRIALSderived15 of 143show all (up to 200)
→ investigated in trials for	Pembrolizumabmonoclonal_antibody 140 trials (76 active) · roll-up of the cancer and its descendants	—	—	Triple-Negative Breast Carcinoma	140	Observed	clinicaltrials	graph →
→ investigated in trials for	Carboplatinsmall_molecule 102 trials (52 active) · roll-up of the cancer and its descendants	—	—	Triple-Negative Breast Carcinoma	102	Observed	clinicaltrials	graph →
→ investigated in trials for	Paclitaxelsmall_molecule 93 trials (46 active) · roll-up of the cancer and its descendants	—	—	Triple-Negative Breast Carcinoma	93	Observed	clinicaltrials	graph →
→ investigated in trials for	Cyclophosphamidesmall molecule 70 trials (33 active) · roll-up of the cancer and its descendants	—	—	Triple-Negative Breast Carcinoma	70	Observed	clinicaltrials	graph →
→ investigated in trials for	Nab-paclitaxel 58 trials (24 active) · roll-up of the cancer and its descendants	—	—	Triple-Negative Breast Carcinoma	58	Observed	clinicaltrials	graph →
→ investigated in trials for	Capecitabinesmall molecule 45 trials (23 active) · roll-up of the cancer and its descendants	—	—	Triple-Negative Breast Carcinoma	45	Observed	clinicaltrials	graph →
→ investigated in trials for	Doxorubicinsmall molecule 39 trials (18 active) · roll-up of the cancer and its descendants	—	—	Triple-Negative Breast Carcinoma	39	Observed	clinicaltrials	graph →
→ investigated in trials for	Gemcitabinesmall_molecule 33 trials (14 active) · roll-up of the cancer and its descendants	—	—	Triple-Negative Breast Carcinoma	33	Observed	clinicaltrials	graph →
→ investigated in trials for	Sacituzumab Govitecanadc 32 trials (23 active) · roll-up of the cancer and its descendants	—	—	Triple-Negative Breast Carcinoma	32	Observed	clinicaltrials	graph →
→ investigated in trials for	Atezolizumabmonoclonal_antibody 26 trials (7 active) · roll-up of the cancer and its descendants	—	—	Triple-Negative Breast Carcinoma	26	Observed	clinicaltrials	graph →
→ investigated in trials for	Cisplatinsmall_molecule 21 trials (7 active) · roll-up of the cancer and its descendants	—	—	Triple-Negative Breast Carcinoma	21	Observed	clinicaltrials	graph →
→ investigated in trials for	Docetaxelsmall molecule 21 trials (11 active) · roll-up of the cancer and its descendants	—	—	Triple-Negative Breast Carcinoma	21	Observed	clinicaltrials	graph →
→ investigated in trials for	Olaparibsmall_molecule 21 trials (11 active) · roll-up of the cancer and its descendants	—	—	Triple-Negative Breast Carcinoma	21	Observed	clinicaltrials	graph →
→ investigated in trials for	Bevacizumabmonoclonal antibody 20 trials (10 active) · roll-up of the cancer and its descendants	—	—	Triple-Negative Breast Carcinoma	20	Observed	clinicaltrials	graph →
→ investigated in trials for	Eribulinsmall_molecule 20 trials (8 active) · roll-up of the cancer and its descendants	—	—	Triple-Negative Breast Carcinoma	20	Observed	clinicaltrials	graph →

Triple-Negative Breast Carcinoma studied in …STUDIED_INderived10 of 948show all (up to 200)
→ studied in	NCT05007106Phase 2 · completed MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) (KEYVIBE-005) · condition mapped ALIAS · 948 trials mapped (452 active)	—	—	Triple-Negative Breast Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT06586957Phase 1 · recruiting A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors · condition mapped ALIAS · 948 trials mapped (452 active)	—	—	Triple-Negative Breast Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT07698106Phase 1/Phase 2 · not yet recruiting Enhancing ICB Efficacy Through IL-1 Inhibition in TNBC · condition mapped ALIAS · 948 trials mapped (452 active)	—	—	Triple-Negative Breast Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT02498613Phase 2 · active not recruiting A Phase 2 Study of Cediranib in Combination With Olaparib in Advanced Solid Tumors · condition mapped CURATED_BROADER · 948 trials mapped (452 active)	—	—	Triple-Negative Breast Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT02945579NA · recruiting Multicenter Trial for Eliminating Breast Cancer Surgery or Radiotherapy in Exceptional Responders to Neoadjuvant Systemic Therapy · condition mapped ONTOLOGY_EXACT · 948 trials mapped (452 active)	—	—	Triple-Negative Breast Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT04981119recruiting Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing · condition mapped ALIAS · 948 trials mapped (452 active)	—	—	Triple-Negative Breast Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT05528133Phase 2 · recruiting Genomically Guided Radiation Therapy in the Management of Triple Negative Breast Cancer · condition mapped ALIAS · 948 trials mapped (452 active)	—	—	Triple-Negative Breast Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT06393374Phase 3 · recruiting Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012) · condition mapped ALIAS · 948 trials mapped (452 active)	—	—	Triple-Negative Breast Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT06799065Phase 1/Phase 2 · recruiting First-in-Human Study of ATX-295, an Oral Inhibitor of KIF18A, as Monotherapy and in Combination With Anticancer Therapy in Patients With Advanced or Metastatic Solid Tumors, Including Ovarian Cancer · condition mapped ALIAS · 948 trials mapped (452 active)	—	—	Triple-Negative Breast Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT06841354Phase 3 · recruiting A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011) · condition mapped ALIAS · 948 trials mapped (452 active)	—	—	Triple-Negative Breast Carcinoma	1	Observed	clinicaltrials	graph →